Brain cancer vaccine in mid-stage trail

Biotech company Celldex Therapeutics announced that their experimental vaccine to extend the lives of brain cancer patients is in midstage trial.

According to Reuters:
The trial, named ACT III, showed 66 percent of patients had no disease progression at 5.5 months from the start of vaccination, a statistically significant increase over a predetermined progression-free rate estimate of 53 percent, with standard of care.

Celldex has the only other FDA approved cancer vaccine on the market, a vaccine for advanced prostate cancer.

Share this article with your social network, just click below to share now!

Share |